GenomeDx's Decipher Shows Broad Applicability in Advancing Prostate Cancer Care in Data Presented at 2015 ASCO Genitourinary Symposium

Data from Multiple Studies Include Potential Ability for Technology to Further Subtype Patients, Guide Treatment Decisions

Feb 24, 2015, 09:00 ET from GenomeDx Biosciences

SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that data presented at the 2015 ASCO Genitourinary Symposium shows further development of its prostate cancer test, Decipher®.   Results from three new studies highlight data on the combination of genomic markers with MRI for improved diagnosis, and the identification of prostate cancer patient subtypes that may influence response to treatment at different stages of the disease. The studies featuring the findings will be presented on February 26 at the 2015 ASCO Genitourinary Symposium from 11:30 a.m. to 1:00 p.m. ET in Orlando, FL.

"GenomeDx has built the largest genomic database for prostate cancer, with data that follows patient tumor cases over 5, 10 or even 20 years," said Doug Dolginow, MD, CEO of GenomeDx. "With this database, we are showing that we can identify molecular signatures with the potential to answer multiple clinical questions that have meaningful implications for treatment decisions. This will take us well beyond the current clinical applications of Decipher, as we continue to identify the genomic subtypes of patients that may respond uniquely to treatment at different stages of disease."

In a study presented by Scott A. Tomlins, M.D., Ph.D., of University of Michigan, Decipher was used to profile 1,577 patients and define three major prostate cancer molecular subtypes. The study found that molecular subtypes may arise early in the development of the disease and have potential to be used in guiding use of hormone therapy and chemotherapy. The abstract, titled "Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes," will be presented at board B1 during the poster session.

In a study presented by Kosj Yamoah, M.D., Ph.D., of Thomas Jefferson University, researchers identified a subset of prostate cancer biomarkers that predict race-dependent clinical outcomes. These findings may explain the biological contribution to racial disparity observed in prior studies of comparing outcomes of prostate cancer patients of African and European decent. The abstract, titled "A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer," will be presented at board B16 during the poster presentation.

In a study presented by R. Stoyanova, Ph.D., of University of Miami, researchers found a high concordance between genomic information and imaging features across multiple tumors in MRI-directed biopsies. The study is the first to demonstrate that genomics and advanced imaging may be combined to lead to improvements in the diagnosis of clinically significant prostate cancer. The abstract, titled "Using radiomics to characterize MRI-guided prostate cancer biopsy heterogeneity," will be presented at board B17 during the poster presentation. 

About Decipher®

The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.

Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.

Learn more at:

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.

Learn more at:

Media Contact:
Ian Stone
Canale Communications


SOURCE GenomeDx Biosciences